9 results about "Pain control" patented technology

A wearable brain multi-stimulation pain control device is provided, comprising a main support unit, an auxiliary support unit, an audio stimulation unit, and an optical frequency-flashed stimulation unit. The main support unit includes two ear portions corresponding to a user's ears and a front side portion, and the auxiliary support unit includes a mounting portion. Two opposite ends of the mounting portion are pivoted to the main support unit, and the audio stimulation unit includes two speakers that are respectively arranged on the ear portions and can broadcast a binaural beats with frequency following response. The optical frequency-flashed stimulation unit is arranged on the front side portion and can stimulate at least one eye of the user with flickering light, so that the user can obtain multiple stimulations at the same time in a single course of treatment to achieve the effect of improving pain.

Provided is a pharmaceutical composition for use in treating postsurgical pain. The pharmaceutical composition comprises a lipid-based complex. The lipid-based complex comprises an amide-type anesthetic and at least one lipid, wherein a molar ratio of the amide-type anesthetic to the at least one lipid of the lipid-based complex is at least 0.5:1. The total amount of the amide-type anesthetic is at least 1.5 to 5 times of a standard therapeutic dose for treating postsurgical pain with the amide-type anesthetic to achieve an improved pain control with desired prolonged analgesic effect.

A method for treating joint pain in an individual chronically afflicted with osteoarthritis, the method comprising administering to the osteoarthritis individual repeat doses of a liposomal composition comprising an effective amount of an intra-articular corticosteroid or a pharmaceutically acceptable salt thereof, in an intra-articular administration manner. A robust and long-lasting intra-articular corticosteroid treatment efficacy response is achieved for more than one year, without any signs or symptoms of adrenal insufficiency in the individual.

The present application relates to a kind of microdroplet photodynamic therapy compositions for treating skin and mucous membrane squamous cell carcinoma and its preparation method, belong to medical technical field.The microdroplet photodynamic therapy compositions for treating skin and mucous membrane squamous cell carcinoma, including photosensitizer precursor, anesthetic and solvent, the mass final concentration of the photosensitizer precursor is 15-25 %, the mass final concentration of the anesthetic is 4-6 %, and the photosensitizer precursor is hydrochloric acid aminolevulinic acid.The microdroplet photodynamic therapy compositions for treating skin and mucous membrane squamous cell carcinoma prepared by the present application adopts the mode of microdroplet injection, solves the three big problems of drug delivery, function preservation and pain control commonly faced in the treatment of different sensitive parts (face, hand, genital organ, tongue), enhances the practicability of the microdroplet photodynamic therapy compositions for treating skin and mucous membrane squamous cell carcinoma of the present application.

The invention provides an embolism microsphere for chronic musculoskeletal system pain control and a preparation method and application thereof, and belongs to the technical field of medicine. The polysaccharide-absorbable embolism microsphere is prepared by effectively wrapping antibiotic particles inside the polysaccharide-absorbable embolism microsphere. After the embolism microsphere reaches a target blood vessel, the antibiotic particles can be slowly released along with degradation of the polysaccharide microsphere, and the embolism microsphere provided by the invention is simple in preparation process, easy for large-scale production and capable of better meeting clinical use requirements.

Methods of applying a solid forming local anesthetic formulations can include applying a layer of a solid-forming formulation to a skin surface, wherein the solid-forming local anesthetic formulation includes from 4 wt % to 30 wt % of a local anesthetic, less than 36 wt % dicalcium phosphate, water, and a polymer. These methods can further include maintaining the layer of the formulation on the skin surface for a period of time sufficient to allow the layer of the formulation to transition from a semi-solid to a cohesive film and to topically deliver the local anesthetic to the skin surface, and removing the layer of the formulation from the skin surface by peeling the layer of the formulation off the skin surface. The layer of the formulation can be operable to be removed as a single piece or two to three large pieces.

Disclosed are methods for a novel, counter-intuitive, non-obvious, non-invasive, simple to administer, non-systemic delivery of analgesics through the skin to the DRG and DH area to block and relieve pain in the dermatomal distribution of that particular DRG. This method of pain control provides a non-addictive, inexpensive, simple to use alternative to the present standard of care involving addictive, potentially dangerous opioid therapy.

A composition having effects on improving unidentified complaints, depression, impaired concentration, decreased motivation for socialization and daily activities, autonomic nervous system disorders, pain, control and poor sleep quality associated with menstruation is provided. The composition comprises Apocynum venetum leaf extract for improving unidentified complaints, depression, impaired concentration, decreased motivation for socialization and daily activities, autonomic nervous system disorders, pain, control and poor sleep quality associated with menstruation.

The present invention provides a structured, biologically based clinical method for mitigating symptomatic pulpal conditions and preventing unnecessary endodontic treatment. Targeted at teeth with vital pulps and reversible inflammation, the protocol combines selective caries removal, pulp protection using calcium hydroxide or MTA, a sedative zinc oxide-eugenol base, and provisional sealing with moisture-setting cement. The method includes diagnostic, therapeutic, and follow-up steps, with one-week, one-month, and three-month evaluations to assess healing. If symptoms persist, root canal therapy is initiated; if asymptomatic, definitive restoration is performed. Annual monitoring ensures long-term pulpal stability. This reproducible approach prioritizes pain control, infection management, pulp preservation, and tooth longevity. It provides an evidence-based alternative to conventional endodontics, reducing overtreatment while supporting functional and biological integrity of the dental organ.